Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks License, Collaborators for HPV-related Cervical Cancer miRNAs

NEW YORK (GenomeWeb News) – The National Institutes of Health has made available for licensing miRNA technology that could be used to develop a diagnostic or a therapeutic for cervical cancer tumors related to cases of human papillomavirus.
 
The NIH also said it is seeking statements of capability or interest from parties who may wish to engage in collaborative research to develop, evaluate, or commercialize the p53 specific miR-34, which it said is downregulated in HPV-infected primary keratinocytes. The miR-34 has been shown to arrest the cell cycle at a certain phase in tumor development and to promote apoptosis.
 
Information about the miRNA technology was published in 2007 in the July issue of Cancer Research and the Nov. 12 edition of Oncogene
 

The miRNA technology’s provisional application, number 60/983,368, was filed in October 2007, and its reference number is E-029-2008/0-US-01.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.